Synopsis: Enalapril maleate 1 is an orally active angiotensin-converting enzyme inhibitor. It
lowers peripheral vascular resistance without causing an increase in heart rate. Enalapril 10 …

Enalapril maleate is a prodrug which when administered orally is hydrolysed to release the
active converting enzyme inhibitor enalaprilat. Enalapril maleate is 60% absorbed and 40 …

FIVE years ago Atkinson and Robertson surveyed the use of captopril, the first orally active
inhibitor of the renin-angiotensin system, in the treatment of clinical hypertension and …

The chemistry, pharmacology, pharmacokinetics, adverse effects, and dosages of the three
currently available angiotensin-converting enzyme (ACE) inhibitors are reviewed. This class …

• The purpose of this study was to define the effect of the angiotensin-converting enzyme
inhibitor, enalapril maleate, on blood pressure, renal function, protein excretion, and …

Teprotide, a nonapeptide isolated from the venom of a Brazilian pit viper, Bothrops jararaca,
was the first angiotensin converting enzyme (ACE) inhibitor to be discovered and tested. It …

Patient 1. A 46-year-old school teacher went to his family physician because of a nose
bleed. He had suffered from frequent headaches for the previous 15 years and during the …

Fifteen patients presented between January 1986 and January 1991 with deterioration in
renal function coincident with the introduction of angiotensin converting enzyme inhibitors …

Lisinopril is a new, nonsulfhydryl angiotensin-converting enzyme inhibitor approved for the
treatment of hypertension. After oral administration, 25–29 percent of the dose is absorbed …

Introduction: The mechanism by which hypertension is maintained in renovascular
hypertension remains poorly defined. Because plasma angiotensin II does not correlate with …